ARCHIVE TOPICS

• January-March 2017
  Effects of Small-Molecule Kinase Inhibitors on Isolated Rat Liver Mitochondria
  FDA Liver Toxicity Working Group Workshop
  New Technologies to Supplement Animal Studies in Evaluating Drugs for Liver Toxicity Risk
  Development of Computational Models of hERG Potassium Channel Binding
  Evaluation of Antimicrobial Effects of Silver-Containing Food Contact Materials
  Cadmium Affects Gene Expression During Differentiation of Mouse Embryonic Stem Cells
  Sex and Age Differences in miRNA Expression in Rat Liver
  In Vitro to in Vivo Extrapolation (IVIVE) for Drug-Induced Liver Injury (DILI)
  Epigenetic Mechanisms in Pathogenesis of Acute Kidney Injury (AKI)
  Mid-South Computational Biology and Bioinformatics Society (MCBIOS) Conference
  Effects of β-lactam Antibiotics on Resistance Development and Penicillin-Binding Proteins in Clostridium perfringens   

• April-June 2017
  Developmental Neurotoxicity Associated With Pediatric General Anesthesia
  Risk Evaluation of Perchlorate Exposure in Pregnant Women Using Probabilistic Biologically Based Dose-Response (BBDR) Modeling
  Effects of Mucous-Penetrating Nanoparticles in a Cultured Vaginal Epithelial Cell Model
  Evaluating Toxicity of Tobacco Smoke Solutions in an In Vitro Air-Liquid-Interface Airway Model
  NCTR Conducting Study as Part of FDA Research on Gadolinium-Based Contrast Agents (GBCAs) for Magnetic Resonance Imaging
  Neurodegenerative Markers are Increased in Postmortem BA21 Tissue from African Americans with Alzheimer’s Disease (AD)
  Nanotechnology Training at NCTR
  Save the Date: 2017 Global Summit for Regulatory Science

• August-September 2017
  
  Lessons Learned from Two Decades of Anticancer Drugs  
  
  Tremendous efforts have been made to understand cancer biology for advancing anticancer drug development. Despite two decades of intensive research efforts, only a little over 200 anticancer drugs have been made available. The low throughput is in large part due to anticancer drug development still suffering high attrition during the later phases of clinical development. 
  
  NCTR scientists in collaboration with scientists from University of Birmingham in the UK and University of Arkansas at Little Rock summarized both successful and failed experiences in anticancer development during the past 20 years.  The work helped identify why the current paradigm may be suboptimal. Furthermore, they offer potential strategies for improvement of anticancer drug development. This publication is now available online at Trends in Pharmacological Sciences.
  
  For more information, please contact Zhichao Liu, Ph.D., Division of Bioinformatics and Biostatistics, FDA/NCTR or Weida Tong, Ph.D., Director, Division of Bioinformatics and Biostatistics, FDA/NCTR.